|
|
|
Sunday, February 12, 2006 — 1:30 PM — Centennial III, IV
|
- Pathology of Cutaneous Lymphoproliferative Disorders
|
|
Moderators:
|
Lawrence M. Weiss, City of Hope Medical Center, Duarte, CA and Lyn M. Duncan, Harvard Medical School, Massachusetts General Hospital, Boston, MA
|
|
|
Disclosure:
|
The speakers have indicated they have nothing to disclose.
|
 Click here to download handout in 1-per-page format for the entire meeting (432KB)
Click here to download handout in 6-per-page format for the entire meeting (669KB)
Click any blue title below to display and print the handout for individual lecture(s):
| 1:30 | Mycosis Fungoides and Variants - Jennifer McNiff, Yale School of Medicine, New Haven, CT |
| 2:00 | CD30+ Lymphoproliferative Disorders of the Skin - Marsha Kinney, University of Texas Health Sciences Center, San Antonio, TX |
| 2:30 | Other Cutaneous T, NK, and Precursor Lymphomas - Dan Jones, MD Anderson Cancer Center, Houston, TX |
| 3:00 | Break |
| 3:30 | Cutaneous B—cell Lymphoma - Lyn Duncan, Harvard Medical Schoool, Massachusetts, General Hospital, Boston, MA |
| 4:00 | Secondary Lymphomas of the Skin - Daniel A. Arber, Stanford University, Stanford, CA |
| 4:30 | Benign Mimics of Cutaneous Lymphomas - Martin C. Mihm, Jr., Harvard Medical School, Massachusetts General Hospital, Boston, MA |
| Selection of a topic for this symposium was chosen because of the important educational aspects resulting from the complexity of the subject, the interest in skin lymphomas in the community, and recent changes in the classification as evidenced by the new EORTC/WHO classification just published. Skin lymphomas are common and problematic in terms of diagnosis and management to both the pathology and dermatology community. There have been significant recent advances in classification of these neoplasms, particularly in the European and World Health Organization classifications which have recently been reconciled. Considerable new and important data regarding these neoplasms has arisen from new techniques such as gene expression profiling in cutaneous lymphomas. This topic has not been previously discussed in depth at one of the society’s symposia. |
|
|
|
